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LETTERS TO THE EDITOR
Response in post-menopausal patients on ICI 118630
Sir - We were surprised to read in your journal the
conclusion of Plowman et al. (1986) that 'two post-
menopausal women showed an objectively measured
response and durable remission of metastatic breast cancer
(in bone and lungs respectively) following therapy with the
potent LHRH analogue ICI 118630'.
From the data presented by the authors we would point
out the following - We accept that the eight non-responders
were post-menopausal being either over 60 years of age or
having had bilateral oophorectomy performed. However, of
the two 'responders', patient 2 had her last period only 3
years previously and from her hormone levels had some
ovarian function which would be blocked by Zoladex.
Although patient 1 was post-menopausal we would point out
that a bone scan is not accepted in the UICC criteria
(Hayward et al., -1977) for the objective measurement of
response in patients with metastatic breast cancer. Finally it
was reported that the bone scan showed 'improvement' after
3 months at which time therapy was changed and that this
was regarded as 'remission'. Response of only 3 months is
poor and we regard 6 months as the usual criteria for useful
response as' outlined in the British Breast Group (1974)
criteria. We also note that Plowman et al. speak of
'remission' rather than response and hope that this is not a
semantic trap.
Plowman et al. may be correct when they state that ICI
118630 could theoretically have a direct effect on breast
cancer cells and thereby produce a response in post-
menopausal women. However, from their own data we do
not believe that they have shown objectively measured and
durable response in post-menopausal women on ICI 118630.
Yours etc.,
J.F.R. Robertson & R.W. Blamey,
Department of Surgery,
City Hospital,
Nottingham NG5 1PB, UK.
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Dr Plowman replies:
Sir - I am pleased to answer Robertson and Blamey's
comments. I confirm that patient 2 was 3 years post-
menopausal, had raised gonadotrophin levels and that both
serum oestradiol and serum oestrone levels were in post-
menopausal range prior to treatment and that the sex
steroids were not influenced by that treatment. I confirm
that the nature of the bone metastatic disease in patient 1
was reported (and documented in the published manuscript)
as typical of metastatic disease on both plain X-ray and CT
scanning of the vertebrae and that (as is clearly shown in
Figure 1 of the manuscript) this reverted to normal on the
bone scan by day 89 of treatment. I confirm (as clearly
stated) that ethical committee approval for the drug ceased
at 3 months and that this was the the reason for the
alteration in drug therapy at this time; the figure included a
day 496 scan to demonstrate the classical behaviour of
breast cancer, when relapsing after endocrine therapy, to
progress at previous sites of disease - so well known to
physicians. I confirm that the sequel to a good response is a
remission. The various ramifications of these observations
are discussed in the manuscript.
Yours etc.,
P.N. Plowman,
Department of Radiotherapy,
St. Bartholomew's Hospital,
London EClA 7BE, UK.